Modulating the immune response to prevent immunogenicity/anti-drug antibodies
17 Jun 2025
Immunogenicity
- Biotherapeutic modalities – What are the Inherent immunogenicity potentials and their relevance?
- Should we be worried about immunogenicity of the gene-editing components and its expressed gene product?
- How do biological mechanisms underlying immunogenicity offer opportunities for risk mitigation?
- State of the art tools for risk assessment and their relevance to clinical translation – are we ready to ditch preclinical immunogenicity studies?
